Bendamustine

• UNSPSC Description:

  Bendamustine (SDX-105 free base), a purine analogue, is a DNA cross-linking agent. Bendamustine activates DNA-damage stress response and apoptosis. Bendamustine has potent alkylating, anticancer and antimetabolite properties[1].

• Target Antigen:

  Apoptosis; DNA Alkylator/Crosslinker

• Type:

  Reference compound

• Related Pathways:

  Apoptosis;Cell Cycle/DNA Damage

• Field of Research:

  Cancer

• Assay Protocol:

  https://www.medchemexpress.com/Bendamustine.html

• Smiles:

  O=C(O)CCCC1=NC2=CC(N(CCCl)CCCl)=CC=C2N1C

• Molecular Weight:

  358.26

• References & Citations:

  [1]Leoni LM, et al. Bendamustine (Treanda) displays a distinct pattern of cytotoxicity and unique mechanistic features compared with other alkylating agents. Clin Cancer Res. 2008 Jan 1;14(1):309-17.|[2]Cives M, et al. Bendamustine overcomes resistance to melphalan in myeloma cell lines by inducing cell death through mitotic catastrophe. Cell Signal. 2013 May;25(5):1108-17.|[3]Ackler S, et al. Navitoclax (ABT-263) and bendamustine ± rituximab induce enhanced killing of non-Hodgkin's lymphoma tumours in vivo. Br J Pharmacol. 2012 Oct;167(4):881-91.Leukemia. 2023 Sep 26.|J Biomed Res. 2017 0(0): 1-12.|J Mol Med (Berl). 2019 Aug;97(8):1183-1193.|Patent. US20160222465A1.

• Shipping Conditions:

  Blue Ice

• CAS Number:

  16506-27-7